文献速递血管炎

基线可溶性免疫检查点与PR3-ANCA血管炎诱导缓解后复发风险的关联

Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission.
PubMed 文献 · Ann Rheum Dis · 2022-08-16

在RAVE试验的189份基线血浆样本中,MPO-ANCA血管炎患者(n=62)的sTim-3、sCD27、sLag-3、sPD-1和sPD-L2浓度高于PR3-ANCA血管炎患者(n=127)。利妥昔单抗诱导组(n=95)中,sLag-3低(<90 pg/mL)合并sCD27高(>3000 pg/mL)预测治疗失败;6个月达缓解的73例中24例(32.9%)随访期复发,该亚组基线sTim-3(>1200 pg/mL)、sCD27(>1250 pg/mL)和sBTLA(>1000 pg/mL)高值与持续缓解及感染并发症相关。上述发现在环磷酰胺/硫唑嘌呤组94例中未能复制。

要点

  • MPO-ANCA患者基线sTim-3、sCD27、sLag-3、sPD-1、sPD-L2浓度高于PR3-ANCA患者。
  • 利妥昔单抗组sLag-3<90 pg/mL合并sCD27>3000 pg/mL预测治疗失败。
  • 利妥昔单抗组缓解后复发者基线sTim-3、sCD27、sBTLA高值与持续缓解及感染相关。

核心结论

  • 利妥昔单抗治疗的AAV患者中,sLag-3低且sCD27高时达缓解率较低。
  • 利妥昔单抗治疗者基线sTim-3、sCD27和sBTLA高值预测复发。
  • 这些结果需进一步确认,但可能有助于AAV的个体化治疗。

研究设计与样本

  • 于RAVE试验开展期间,用免疫吸附 assay 测定可获得样本的血浆sICP浓度,纳入PR3-ANCA或MPO-ANCA血管炎患者,并与临床结局、一组生物标志物及可获得的聚焦T细胞亚群的流式细胞术分析进行关联。
  • 用log-rank检验评估生存获益,用Yeldon J计算标志分子的最佳截断值。
  • 分析基线189份血浆样本,其中MPO-ANCA血管炎62例、PR3-ANCA血管炎127例。

主要发现

  • 基线时MPO-ANCA血管炎患者(n=62)的sTim-3、sCD27、sLag-3、sPD-1和sPD-L2浓度高于PR3-ANCA血管炎患者(n=127)。
  • 接受利妥昔单抗诱导治疗的患者(n=95)中,sLag-3低(<90 pg/mL)合并sCD27高(>3000 pg/mL)预测治疗失败。
  • 利妥昔单抗组6个月达缓解的73例中24例(32.9%)在随访期间复发。
  • 该亚组中基线sTim-3(>1200 pg/mL)、sCD27(>1250 pg/mL)和sBTLA(>1000 pg/mL)高值与持续缓解及感染并发症均相关。
  • 随机接受环磷酰胺/硫唑嘌呤治疗的94例患者中未能复制上述发现。

关键数值与推荐

  • 利妥昔单抗诱导组治疗失败预测:sLag-3<90 pg/mL且sCD27>3000 pg/mL。
  • 利妥昔单抗组复发相关基线阈值:sTim-3>1200 pg/mL、sCD27>1250 pg/mL、sBTLA>1000 pg/mL。
  • 利妥昔单抗组6个月缓解者73例中24例(32.9%)随访期复发。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出这些结果需进一步确认(require confirmation)。
  • 上述发现在随机接受环磷酰胺/硫唑嘌呤治疗的94例患者中未能复制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We investigated whether soluble immune checkpoints (sICPs) predict treatment resistance, relapse and infections in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). METHODS: Plasma sICP concentrations from available samples obtained during conduct of the RAVE trial were measured by immunoabsorbent assays from patients with either proteinase 3 (PR3) or myeloperoxidase (MPO)-ANCA vasculitis and were correlated with clinical outcomes, a set of biomarkers and available flow cytometry analyses focusing on T cell subsets. Log-rank test was used to evaluate survival benefits, and optimal cut-off values of the marker molecules were calculated using Yeldons J. RESULTS: Analysis of 189 plasma samples at baseline revealed higher concentrations of sTim-3, sCD27, sLag-3, sPD-1 and sPD-L2 in patients with MPO-ANCA vasculitis (n=62) as compared with PR3-ANCA vasculitis (n=127). Among patients receiving rituximab induction therapy (n=95), the combination of lower soluble (s)Lag-3 (<90 pg/mL) and higher sCD27 (>3000 pg/mL) predicted therapy failure. Twenty-four out of 73 patients (32.9%) in the rituximab arm reaching remission at 6 months relapsed during follow-up. In this subgroup, high baseline values of sTim-3 (>1200 pg/mL), sCD27 (>1250 pg/mL) and sBTLA (>1000 pg/mL) were associated with both sustained remission and infectious complications. These findings could not be replicated in 94 patients randomised to receive cyclophosphamide/azathioprine. CONCLUSIONS: Patients with AAV treated with rituximab achieved remission less frequently when concentrations of sLag-3 were low and concentrations of sCD27 were high. Higher concentrations of sTim-3, sCD27 and sBTLA at baseline predicted relapse in patients treated with rituximab. These results require confirmation but may contribute to a personalised treatment approach of AAV.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Gamerith G, Mildner F, Merkel PA, et al. Association of baseline soluble immune checkpoints with the risk of relapse in PR3-ANCA vasculitis following induction of remission. Ann Rheum Dis. 2022. PMID: 35973802. doi:10.1136/ard-2022-222479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。